

Клинические аспекты медицины
транспорта

Clinical Aspects of Transport
Medicine

УДК 618.11-006.6:615.277.3.015.46 <http://dx.doi.org/10.5281/zenodo.3967622>

**ACTUAL APPROACHES TO PLATINUM RESISTANCE MANAGEMENT
IN PATIENTS WITH THE SEROUS OVARIAN CANCER**

Rybin A.I.

Odessa National Medical University, Ukraine

**АКТУАЛЬНІ ПІДХОДИ ДО УПРАВЛІННЯ РЕЗИСТЕНТНІСТЬЮ ДО
ПЛАТИНИ У ХВОРИХ НА СЕРОЗНИЙ НА РАК ЯЄЧНИКІВ**

Рибін О.І.

Одеський національний медичний університет, Україна

**АКТУАЛЬНЫЕ ПОДХОДЫ К УПРАВЛЕНИЮ РЕЗИСТЕНТНОСТЬЮ
К ПЛАТИНЕ У БОЛЬНЫХ С СЕРОЗНЫМ РАКОМ ЯИЧНИКОВ**

Рыбин А.И.

Одесский национальный медицинский университет, Украина

Summary/Резюме

30

Мета дослідження - визначити біомаркери резистентності до платини у пацієнтів з раком яєчників. Експресія ABCA1 вище в стійких до платини випадках раку яєчників. Найбільш виражений зв'язок існує між значеннями експресії сурвівіна, локальною активністю оксиду азоту, експресією глутатіон-залежних ферментів, вмістом катехоламінів в еритроцитах і експресією переносника ABCA1.

Ключові слова: рак яєчників, резистентність до платини, біомаркери.

Цель исследования - определить биомаркеры резистентности к платине у пациентов с раком яичников. Экспрессия ABCA1 выше в устойчивых к платине случаях рака яичников. Наиболее выраженная связь существует между значениями экспрессии сурвивина, локальной активностью оксида азота, экспрессией глутатион-зависимых ферментов, содержанием катехоламинов в эритроцитах и экспрессией переносчика ABCA1.

Ключевые слова: рак яичников, резистентность к платине, биомаркеры.

The study was aimed to determine the platinum-resistance biomarkers in patients with ovarian cancer. The expression of ABCA1 is higher in platinum-resistant cases of ovarian cancer. The most pronounced relationship exists between the values of survivin expression, local activity of nitric oxide, the expression of glutathione dependent enzymes, the content of catecholamines in erythrocytes, and the expression of ABCA1 transporter

Key words: ovarian cancer, platinum resistance, biomarkers

Introduction

According to the International Agency for Research on Cancer, more than 165,000 new cases of ovarian cancer are

reported annually in the world and more than 100,000 women die from malignant ovarian tumors. According to mortality rates, ovarian cancer ranking 5th among

the causes of death from all tumors in women. The mortality of patients with ovarian cancer in the first year after diagnosis is 35% [1, 2]. Overall five-year survival rate of patients with ovarian cancer does not exceed 35-40% [3]. These circumstances are due to the asymptomatic flow of ovarian cancer in the early stages, which leads to late diagnosis of the disease, when radical surgical intervention is not possible.

The problem of ovarian cancer has a huge medical and social significance. According to the aggregated data of population cancer registries of European countries, one-year survival rate of patients with MS is 63%, three years - 41%, five years - 35%. In the last decade in Europe, the increase in the five-year survival rate of patients with malignant tumors of the ovaries by 3% (from 32 to 35%), and in the United States - by 4% (from 35 to 39%) is due not so much to improving diagnosis, but due to implementing effective platinum-based chemotherapy in the treatment of disseminated forms of ovarian cancer and germinogenic tumors [4, 5].

To date, the "gold standard" for treatment of the IB-IIIC stages is surgical intervention with the subsequent rate of postoperative chemotherapy. At the same time the drug of choice is platinum preparations. The mechanism of action of platinum derivatives is associated with DNA damage, resulting in the formation of so-called cisplatin-DNA adducts, which, in turn, block replication, transcription and suppress the proliferation of malignantly transformed cells [4].

Resistance to platinum preparations is considered as a multifactorial phenomenon, which is due to a decrease in intracellular cytostatic accumulation, increased activity of glutathione detoxification systems and metallothioneins, disorders of the repair system of damaged DNA etc. [6-8].

Depending on the progression of the

disease, it is customary to distinguish between the following types of ovarian cancer: platinum-refractory (progressing during first-line chemotherapy with the inclusion of platinum preparations), platinum-resistant (progressing within 6 months after the completion of first-line chemotherapy with the inclusion of platinum preparations) and platinum-susceptible (progressing more than 6 months after the completion of first-line chemotherapy) [6].

Purpose of the study: to determine the platinum-resistance biomarkers in patients with ovarian cancer.

Material and methods. The research was performed not on the basis of the regional oncology clinic (Odessa, Ukraine). 29 platinum-resistant patients with verified ovary cancer of IIIB-IIIC stages were examined, who received 6 courses of adjuvant chemotherapy with platinum preparations (cisplatin 75-100 mg/m² intravenously with hydration and forced diuresis every 3 weeks) in the postoperative period. As control, 26 patients with non-recurrence of the disease performed for 6 months post-treatment observation (platinum-susceptible tumors) were observed.

The criteria for the relapse registration, according to FIGO recommendations, were the levels of markers of CA-125, NE4 and CT data of the pelvic organs, abdominal cavity and retroperitoneum, as well as the patient's objective examination [9].

All patients analyzed the possible risk factors for resistance to platinum at the level of the body and tissues, including analysis of clinical and anamnestic characteristics, risk factors for ovarian cancer, analysis of potential predictors of platinum resistance. Expression of endothelial growth factor, vascular endothelial growth factor receptors, cyclin D, cyclin E, p53, pAkt, Bcl-2, sarvinin, ABC transporter A1 in tumor tissue by immunohistochemical method [11] was studied. Additionally, local activity of nitric oxide, expression of catecholamines in erythrocytes and intra-

cellular sulfur activity in tumor tissue [12] were analyzed.

A comparative analysis of the data was carried out using Fischer's exact criterion and the besselial correlation analysis. Statistical analysis of data was carried out using the Statistica 10.0 (Dell StatSoft Inc.) program [13].

Research results

It was found that in platinum-susceptible patients, VEGF expression in tumor tissue was 55 (27; 122) pg/mg, while platinum-resistant 95 (45-147) pg/ml ($p > 0.05$). The expression of VEGFR-1 in platinum-resistant patients was 2.4 (1.9-3.2) pg/ml, and platinum-sensitive 2.5 (2.0-3.0) pg/ml. In contrast, the expression of VEGFR-2 was 170 (120-222) pg/ml and 165 (150-190) pg/ml, respectively ($p > 0.05$). The content of pAkt was 0.2 (0.1- 0,3) pg/ml, and in platinum-sensitive ones - 0,5 (0,3-0,8) pg/ml. The content of Bcl-2 was 45 (25-135) pg/ml and 117 (35-225) pg/ml, respectively. The protein content of p53 in tumor tissue of platinum-sensitive patients was 4.5 ± 0.7 U/ml, while in the tissue of platinum-resistant tumors - 3.9 ± 0.6 U/ml only ($p > 0,05$).

It was also found that in platinum-resistant cases, a positive reaction to the content of survivin was determined both in the cytoplasm and within the nucleus. Instead, in platinum-susceptible patients, in most cases (92.3%) only a positive response was recorded in the cytoplasm.

For platinum-resistant cases of ovarian cancer, the expression of NOS (an average of 1.2 ± 0.2 points) and a high content of intracellular sulfur (3.8 ± 0.2 points) were characteristic declining, whereas in platinum-sensitive cases, respectively, $3.2 \pm 0, 4$ and 2.7 ± 0.3 points ($p < 0.05$).

The content of catecholamines in erythrocytes of patients with ovarian cancer was significantly higher in platinum-resistant cases (up to 3.0 ± 0.03 granules/RBC), whereas in platinum-sensitive cases this figure was 2.6 ± 0.02 granules/RBC.

Positive reaction to cyclin D content was found in 4 (13.8%) platinum-resistant patients, while platinum-susceptible ones were found in 5 (19.2%) patients. Positive response to cyclin E was determined in 6 (20.7%) in platinum-resistant patients and in 4 (15.4%) platinum-susceptible patients. Statistically significant differences were not found for these indices ($p > 0.05$).

Positive reaction to ABCA1 was detected in 9 (31.0%) platinum-resistant and 5 (19.2%) platinum-susceptible ones ($p < 0,05$). In the course of the correlation analysis, it was found that the most pronounced relationship exists between the values of survivin expression, local activity of nitric oxide, the expression of glutathione dependent enzymes, the content of catecholamines in erythrocytes, and the expression of ABCA1 transporter (Table 1).

Table 1

Correlation between the biomarkers of platinum resistance

	VEGFR-1	VGFR-2	pAkt	Bcl-2	p53	Surv.	NOS	S	KCH	C.D	C.E	ABCA1
VEGF	0,12	0,24	-0,08	-0,11	0,16	0,25	0,27	-0,18	-0,09	0,15	0,18	0,26
VEGFR-1		0,22	0,10	-0,09	0,07	0,19	0,21	0,12	0,05	0,11	0,14	0,12
VGFR-2			0,19	-0,08	-0,12	0,15	0,27	0,06	-0,11	0,09	0,12	0,24
pAkt				0,13	-0,02	0,19	0,15	0,09	-0,07	0,18	0,22	0,13
Bcl-2					0,18	0,27	0,13	-0,14	0,17	-0,08	-0,19	0,16
p53						0,23	0,06	-0,17	0,09	0,17	-0,15	0,05
Surv.							0,39	-0,33	0,35	0,28	0,29	0,54
NOS								0,42	0,39	0,30	0,28	0,59
S									0,33	-0,27	-0,28	0,53
KCH										0,31	0,33	0,45
C.D											0,62	0,41
C.E												0,43

The evidence suggests that there are common mechanisms for influencing the platinum resistance processes and the appropriateness of control of the level of expression of survivin, local activity of nitric oxide, expression of glutathione

dependent enzymes, the content of catecholamines in erythrocytes, and the expression of the ABCA1 transporter in tumor tissue in patients with ovarian cancer.

Conclusion

1. The expression of ABCA1 is higher in platinum-resistant cases of ovarian cancer.
2. The most pronounced relationship exists between the values of survivin expression, local activity of nitric oxide, the expression of glutathione dependent enzymes, the content of catecholamines in erythrocytes, and the expression of ABCA1 transporter

References

1. Epidemiology Working Group Steering Committee, Ovarian Cancer Association Consortium Members of the EWG SC, in alphabetical order.; Doherty JA, Jensen A, Kelemen LE, Pearce CL, Poole E, Schildkraut JM, Terry KL, Tworoger SS, Webb PM, Wentzensen N. Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research. *J Natl Cancer Inst.* 2017 Oct 1; 109(10).
2. Doherty JA, Peres LC, Wang C, Way GP, Greene CS, Schildkraut JM. Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes. *Curr Epidemiol Rep.* 2017 Sep;4(3):211-220
3. Ивченко А.Л. Рак яичников: современные аспекты диагностики. Харківська хірургічна школа. 2015. 4(73): 147-51
Ivchenko AL. Ovarian cancer: modern aspects of diagnosis. *Kharkiv surgical school.* 2015.4 (73): 147-51
4. Francis J, Coakley N, Elit L, Mackay H; Gynecologic Cancer Disease Site Group. Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline. *Curr Oncol.* 2017 Dec;24(6):e540-e546.
5. Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Optimizing treatment in recurrent epithelial ovarian cancer. *Expert Rev Anticancer Ther.* 2017 Dec;17(12):1147-1158.
6. Sonogo M, Pellizzari I, Dall'Acqua A, Pivetta E, Lorenzon I, Benevol S, Bomben R, Spesotto P, Sorio R, Gattei V, Belletti B, Schiappacassi M, Baldassarre G. Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. *Sci Rep.* 2017 Aug 2;7(1):7104.
7. Slaughter K, Holman LL, Thomas EL, Gunderson CC, Lauer JK, Ding K, McMeekin DS, Moore KM. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. *Gynecol Oncol.* 2016 Aug;142(2):225-30.
8. Shafrir AL, Babic A, Tamimi RM, Rosner BA, Tworoger SS, Terry KL. Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases. *Br J Cancer.* 2016 Nov 22;115(11):1391-1399.
9. Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2013 Oct;24 Suppl 6:vi24-32
10. Тюляндин С.А., Моисеенко В.М. Практическая онкология. М., 2004 784 с. Tyulandin S.A., Moiseenko V.M. Practical oncology. М., 2004 784 p.
11. Immunohistochemistry (IHC) Handbook Retrieved from https://images.novusbio.com/design/BR_IHC_Guide_011017_web.pdf
12. Рибін А. І., Лисенко М.А., Рисіна А.І. Особливості системи саногенезу у хворих на рак яєчників, що резистентні до хіміотерапії препаратами платини. Збірник наукових праць Асоціації акушерів-гінекологів України. 2014. 1-2. 251-254.
Ribin A. I., Lisenko M. A., Risina A. I. Features of the system of sanogenesis in patients with ovarian cancer who are resistant to chemotherapy with platinum preparations. *Collection of Science Practitioners of the Association of Obstetricians and Gynecologists of Ukraine.* 2014.1-2. 251-254
13. Халафян А.А. Современные статистические методы медицинских исследований. Монография. – М.: 2014. 320
Khalafyan AA Modern statistical methods of medical research. *Monograph.* - М.: 2014.320

*Впервые поступила в редакцию 18.01.2020 г.
Рекомендована к печати на заседании
редакционной коллегии после рецензирования*